Da Silva DM - Search Results

1

Heterozygote advantage at HLA class I and II loci and reduced risk of colorectal cancer.

Tsai YY, Qu C, Bonner JD, Sanz-Pamplona R, Lindsey SS, Melas M, McDonnell KJ, Idos GE, Walker CP, Tsang KK, Da Silva DM, Moratalla-Navarro F, Maoz A, Rennert HS, Kast WM, Greenson JK, Moreno V, Rennert G, Gruber SB, Schmit SL. Tsai YY, et al. Among authors: da silva dm. Front Immunol. 2023 Oct 24;14:1268117. doi: 10.3389/fimmu.2023.1268117. eCollection 2023. Front Immunol. 2023. PMID: 37942321 Free PMC article.

2

Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles.

Rudolf MP, Nieland JD, DaSilva DM, Velders MP, Müller M, Greenstone HL, Schiller JT, Kast WM. Rudolf MP, et al. Biol Chem. 1999 Mar;380(3):335-40. doi: 10.1515/BC.1999.045. Biol Chem. 1999. PMID: 10223336

3

Physical interaction of human papillomavirus virus-like particles with immune cells.

Da Silva DM, Velders MP, Nieland JD, Schiller JT, Nickoloff BJ, Kast WM. Da Silva DM, et al. Int Immunol. 2001 May;13(5):633-41. doi: 10.1093/intimm/13.5.633. Int Immunol. 2001. PMID: 11312251

4

Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro.

Rudolf MP, Fausch SC, Da Silva DM, Kast WM. Rudolf MP, et al. Among authors: da silva dm. J Immunol. 2001 May 15;166(10):5917-24. doi: 10.4049/jimmunol.166.10.5917. J Immunol. 2001. PMID: 11342606

5

Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses.

Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Fausch SC, et al. Among authors: da silva dm. J Immunol. 2002 Sep 15;169(6):3242-9. doi: 10.4049/jimmunol.169.6.3242. J Immunol. 2002. PMID: 12218143

6

HPV protein/peptide vaccines: from animal models to clinical trials.

Fausch SC, Da Silva DM, Eiben GL, Le Poole IC, Kast WM. Fausch SC, et al. Among authors: da silva dm. Front Biosci. 2003 Jan 1;8:s81-91. doi: 10.2741/1009. Front Biosci. 2003. PMID: 12456298 Review.

7

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention.

Wakabayashi MT, Da Silva DM, Potkul RK, Kast WM. Wakabayashi MT, et al. Among authors: da silva dm. Intervirology. 2002;45(4-6):300-7. doi: 10.1159/000067921. Intervirology. 2002. PMID: 12566713

8

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines.

Da Silva DM, Schiller JT, Kast WM. Da Silva DM, et al. Vaccine. 2003 Jul 4;21(23):3219-27. doi: 10.1016/s0264-410x(03)00237-8. Vaccine. 2003. PMID: 12804851

9

Cervical cancer vaccines: recent advances in HPV research.

Eiben GL, da Silva DM, Fausch SC, Le Poole IC, Nishimura MI, Kast WM. Eiben GL, et al. Among authors: da silva dm. Viral Immunol. 2003;16(2):111-21. doi: 10.1089/088282403322017866. Viral Immunol. 2003. PMID: 12828864 Review.

10

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells.

Fausch SC, Da Silva DM, Kast WM. Fausch SC, et al. Among authors: da silva dm. Cancer Res. 2003 Jul 1;63(13):3478-82. Cancer Res. 2003. PMID: 12839929

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

187 results

Search Page